251 related articles for article (PubMed ID: 34733788)
1. ARV-825 Demonstrates Antitumor Activity in Gastric Cancer
Liao X; Qian X; Zhang Z; Tao Y; Li Z; Zhang Q; Liang H; Li X; Xie Y; Zhuo R; Chen Y; Jiang Y; Cao H; Niu J; Xue C; Ni J; Pan J; Cui D
Front Oncol; 2021; 11():753119. PubMed ID: 34733788
[TBL] [Abstract][Full Text] [Related]
2. BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
Wu S; Jiang Y; Hong Y; Chu X; Zhang Z; Tao Y; Fan Z; Bai Z; Li X; Chen Y; Li Z; Ding X; Lv H; Du X; Lim SL; Zhang Y; Huang S; Lu J; Pan J; Hu S
Cancer Cell Int; 2021 Apr; 21(1):230. PubMed ID: 33888130
[TBL] [Abstract][Full Text] [Related]
3. ARV-825 Showed Antitumor Activity against BRD4-NUT Fusion Protein by Targeting the BRD4.
Yang L; Jing Y; Xia X; Yin X
J Oncol; 2023; 2023():9904143. PubMed ID: 38130463
[TBL] [Abstract][Full Text] [Related]
4. BRD4 degrader ARV-825 produces long-lasting loss of BRD4 protein and exhibits potent efficacy against cholangiocarcinoma cells.
Lu Q; Ding X; Huang T; Zhang S; Li Y; Xu L; Chen G; Ying Y; Wang Y; Feng Z; Wang L; Zou X
Am J Transl Res; 2019; 11(9):5728-5739. PubMed ID: 31632543
[TBL] [Abstract][Full Text] [Related]
5. BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor.
Zhang P; Li R; Xiao H; Liu W; Zeng X; Xie G; Yang W; Shi L; Yin Y; Tao K
Int J Biol Sci; 2019; 15(9):1942-1954. PubMed ID: 31523195
[No Abstract] [Full Text] [Related]
6. PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of
Li Z; Lim SL; Tao Y; Li X; Xie Y; Yang C; Zhang Z; Jiang Y; Zhang X; Cao X; Wang H; Qian G; Wu Y; Li M; Fang F; Liu Y; Fu M; Ding X; Zhu Z; Lv H; Lu J; Xiao S; Hu S; Pan J
Front Oncol; 2020; 10():574525. PubMed ID: 33324552
[TBL] [Abstract][Full Text] [Related]
7. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
Saenz DT; Fiskus W; Qian Y; Manshouri T; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Mill CP; Sun B; Qiu P; Kadia TM; Pemmaraju N; DiNardo C; Kim MS; Nowak AJ; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
Leukemia; 2017 Sep; 31(9):1951-1961. PubMed ID: 28042144
[TBL] [Abstract][Full Text] [Related]
8. ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma.
He L; Chen C; Gao G; Xu K; Ma Z
Aging (Albany NY); 2020 Mar; 12(5):4547-4557. PubMed ID: 32163373
[TBL] [Abstract][Full Text] [Related]
9. BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.
Ma L; Wang J; Zhang Y; Fang F; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Sang X; Zhang K; Lu L; Wan X; Chen Y; Yu J; Zhuo R; Wu S; Lu J; Pan J; Hu S
Cancer Biol Ther; 2022 Dec; 23(1):1-15. PubMed ID: 36170346
[TBL] [Abstract][Full Text] [Related]
10. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Coudé MM; Braun T; Berrou J; Dupont M; Bertrand S; Masse A; Raffoux E; Itzykson R; Delord M; Riveiro ME; Herait P; Baruchel A; Dombret H; Gardin C
Oncotarget; 2015 Jul; 6(19):17698-712. PubMed ID: 25989842
[TBL] [Abstract][Full Text] [Related]
11. Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer.
Minko T
Trends Pharmacol Sci; 2020 Oct; 41(10):684-686. PubMed ID: 32893006
[TBL] [Abstract][Full Text] [Related]
12. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
Mu X; Bai L; Xu Y; Wang J; Lu H
Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
[TBL] [Abstract][Full Text] [Related]
14. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
15. BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3.
Ma L; Wang J; Yang Y; Lu J; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Zhang Y; Sang X; Lu L; Wan X; Zhang K; Chen Y; Yu J; Zhuo R; Wu S; Pan J; Zhou X; Hu Y; Hu S
Hematology; 2023 Dec; 28(1):2247253. PubMed ID: 37594294
[TBL] [Abstract][Full Text] [Related]
16. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
[TBL] [Abstract][Full Text] [Related]
17. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera.
Vartak R; Saraswat A; Yang Y; Chen ZS; Patel K
Pharm Res; 2022 Nov; 39(11):2745-2759. PubMed ID: 35146591
[TBL] [Abstract][Full Text] [Related]
19. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
[TBL] [Abstract][Full Text] [Related]
20. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
Lu J; Qian Y; Altieri M; Dong H; Wang J; Raina K; Hines J; Winkler JD; Crew AP; Coleman K; Crews CM
Chem Biol; 2015 Jun; 22(6):755-63. PubMed ID: 26051217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
